Everfront Biotech Holding CO LTD F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
NASDAQ
Everfront Biotech Holding Company Limited, a clinical-stage biopharmaceutical firm, is pursuing an initial public offering to fund its pipeline of cancer and neurodegenerative disease treatments.
NASDAQ
Clinical-stage biopharmaceutical company Everfront Biotech Holding Company Limited announces its plans for an initial public offering on the Nasdaq Capital Market, aiming to raise capital for further clinical trials and drug development.
NASDAQ
Everfront Biotech secures a manufacturing partnership for its lead drug candidate and files an F-1 registration statement for an initial public offering to fund its clinical trials and research efforts.